Clinical trial • Phase IV • Other

DEXMEDETOMIDINE for Thoracoscopic lung resection surgery

Phase IV trial of DEXMEDETOMIDINE for Thoracoscopic lung resection surgery.

Overview

Trial Therapeutic Area
Other
Trial Disease
Thoracoscopic lung resection surgery
Trial Stage
Phase IV
Drug Modality
Small molecule

Key dates

Initial CTIS Submission Date
09-01-2024
First CTIS Authorization Date
02-04-2024

Trial design

Sodium Chloride 0.9% Intravenous Infusion (placebo); max total amount listed: 100 ml; route: intravenous infusion.-controlled Phase IV trial across 1 site in Belgium.

Comparator
Sodium Chloride 0.9% Intravenous Infusion (placebo); max total amount listed: 100 ml; route: intravenous infusion.
Target Sample Size
102

Eligibility

Recruits 102 Participants are adults aged 60 years or older; vulnerable population not selected. Exclusion criterion: "Lack of informed consent or inability to give informed consent" (informed consent required from participant)..

Vulnerable Population
Participants are adults aged 60 years or older; vulnerable population not selected. Exclusion criterion: "Lack of informed consent or inability to give informed consent" (informed consent required from participant).

Inclusion criteria

  • {"criterion_text":"- Adult patients aged 60 years or older"}
  • {"criterion_text":"- Patients scheduled for thoracoscopic lung resection surgery"}

Exclusion criteria

  • {"criterion_text":"- Lack of informed consent or inability to give informed consent"}
  • {"criterion_text":"- 2nd- or higher degree atrioventricular block without pacemaker"}
  • {"criterion_text":"- urgent, not elective surgery"}

Endpoints

Primary endpoints

  • {"endpoint_text":"- (Early) quality of recovery on day 1 following surgery compared to preoperative value, assessed by the quality of recovery score (QoR-15).","definition_or_measurement_approach":"Assessed by the quality of recovery score (QoR-15) comparing day 1 post-surgery to preoperative value."}

Secondary endpoints

  • {"endpoint_text":"- The Quality of Recovery Score (QoR-15) will be used to assess the early postoperative health status of the patient, i.e. the quality of recovery","definition_or_measurement_approach":"Measured using the QoR-15 questionnaire to assess early postoperative health status/quality of recovery."}
  • {"endpoint_text":"- Postoperative muscle strength (lower extremity) and physical ability, assessed by the Timed Up and Go test (TUG)","definition_or_measurement_approach":"Measured by the Timed Up and Go test (TUG) to assess lower extremity strength and physical ability."}
  • {"endpoint_text":"- Postoperative muscle function and decrease in strength (upper extremity) postoperatively will be assessed by comparing the handgrip strength of the dominant hand, measured by the CAMRY dynamometer","definition_or_measurement_approach":"Measured by handgrip strength of the dominant hand using a CAMRY dynamometer; comparison pre/postoperative."}
  • {"endpoint_text":"- To assess general fatigue a fatigue questionnaire, the Chalder fatigue questionnaire, will be taken","definition_or_measurement_approach":"Measured using the Chalder fatigue questionnaire."}
  • {"endpoint_text":"- To assess fatigue more in detail the fatigue VAS scale will be taken","definition_or_measurement_approach":"Measured using a fatigue visual analogue scale (VAS)."}
  • {"endpoint_text":"- The EQ-5D questionnaire will be taken to assess health-related quality of life","definition_or_measurement_approach":"Measured using the EQ-5D questionnaire to assess health-related quality of life."}
  • {"endpoint_text":"- Electroencephalographic (EEG) readings will be conducted (in a subcohort of patients) during the first postoperative night (when administering study medication) via a compact/wearable medical device for recording brain activity","definition_or_measurement_approach":"EEG recordings via a compact/wearable device during the first postoperative night in a subcohort."}
  • {"endpoint_text":"- To evaluate each patient’s sleep-wake cycle, the sleep-wake timing will be evaluated with the Munich ChronoType Questionnaire (MCTQ), which will be used to calculate the baseline midpoint sleep and chronotype","definition_or_measurement_approach":"Assessed via the Munich ChronoType Questionnaire (MCTQ) to calculate baseline midpoint sleep and chronotype."}
  • {"endpoint_text":"- To assess subjective sleep quality the Pittsburgh Sleep Quality Index (PSQI; a seven-item questionnaire consisting of 19 self-rated questions that assess sleep quality over the last month, each weighted equally on a 0-3 scale; higher scores indicate worse sleep quality) will be used","definition_or_measurement_approach":"Measured using the Pittsburgh Sleep Quality Index (PSQI) questionnaire (19 self-rated questions)."}
  • {"endpoint_text":"- The evolution of sleep pre- and postoperatively will be evaluated with the Consensus Sleep Diary to have a more depth insight into the evolution of sleep pre- and postoperatively","definition_or_measurement_approach":"Assessed using the Consensus Sleep Diary to evaluate pre- and postoperative sleep evolution."}
  • {"endpoint_text":"- The Richards-Campbell Sleep Questionnaire (RCSQ) will be taken to evaluate the subjective quality of the first night after surgery","definition_or_measurement_approach":"Measured using the Richards-Campbell Sleep Questionnaire (RCSQ) for subjective quality of the first postoperative night."}
  • {"endpoint_text":"- To assess postoperative delirium the 3 minute confusion assessment method (3D-CAM) questionnaire will be done","definition_or_measurement_approach":"Assessed using the 3D-CAM (3 minute confusion assessment method) questionnaire."}
  • {"endpoint_text":"- To assess postoperative cognitive impairment the Telephone Interview for Cognitive Status (TICS-40) will be done","definition_or_measurement_approach":"Assessed using the TICS-40 (Telephone Interview for Cognitive Status) to evaluate cognitive impairment."}
  • {"endpoint_text":"- NRS pain scores 0-10","definition_or_measurement_approach":"Measured using Numerical Rating Scale (NRS) for pain from 0 to 10."}
  • {"endpoint_text":"- The occurrence of PONV","definition_or_measurement_approach":"Recorded occurrence of postoperative nausea and vomiting (PONV)."}
  • {"endpoint_text":"- Markers of the inflammatory surgical response will be determined","definition_or_measurement_approach":"Measured by laboratory assessment of markers of inflammatory surgical response (details not specified)."}
  • {"endpoint_text":"- Melatonin production will be monitored","definition_or_measurement_approach":"Melatonin production monitoring (method not specified)."}

Recruitment

Planned Sample Size
102
Recruitment Window Months
24
Consent Approach
Informed consent required from participants. Exclusion: "Lack of informed consent or inability to give informed consent." No assent procedures or languages specified.

Geography

Total Number Of Sites
1
Total Number Of Participants
102

Belgium

Earliest CTIS Part Ii Submission Date
04-03-2024
Latest Decision Or Authorization Date
02-04-2024
Processing Time Days
29
Number Of Sites
1
Number Of Participants
102

Sites

Site Name
Ziekenhuis Oost Limburg
Department Name
Critical care department
Principal Investigator Name
Steven Thiessen
Principal Investigator Email
steven.thiessen@zol.be
Contact Person Name
Steven Thiessen
Contact Person Email
steven.thiessen@zol.be
Number Of Participants
102

Sponsor

Primary sponsor

Full Name
Ziekenhuis Oost Limburg
Organisation Type
Hospital/Clinic/Other health care facility
Country Of Registered Address
Belgium

Investigational products

Investigational Product Name
Dexdor 100 micrograms/ml concentrate for solution for infusion
Active Substance
DEXMEDETOMIDINE
Modality
Small molecule
Routes Of Administration
INTRAVENOUS INFUSION
Route
Intravenous infusion
Authorisation Status
Authorised (marketing authorisation EU/1/11/718/006)
Maximum Dose
10 µg/Kg (max total / max daily amount as listed)
Investigational Product Name
Sodium Chloride 0.9% Intravenous Infusion
Active Substance
SODIUM CHLORIDE
Modality
Small molecule
Routes Of Administration
INTRAVENOUS INFUSION
Route
Intravenous infusion
Authorisation Status
Authorised (marketing authorisation PL 08828/0034)
Maximum Dose
100 ml (max total / max daily amount as listed)

Related trials

Other published trials that may interest you.